Are Analyst Price Targets Accurate? 7 Years of Data
How often Wall Street price targets are reached, how long it takes, and how the promised upside compares with what stocks actually did. From Exent’s backtest of 628,792 analyst ratings.
Rudy Li is one of the top‑ranked analysts in Exent’s 7‑year backtest. What Rudy covers, how Rudy’s ratings lean, how fast price targets were reached and the ratings from before the last 30 days; the full record and the newest calls are members‑only.
Rudy Li of Wolfe Research ranks among the top 50 healthcare analysts in Exent’s ranking, with a focus on healthcare. The top of the ranking is what Exent Gems follows, so Rudy’s exact rank, hit rate and live calls are for members.
| Metric | Rudy Li | All analysts |
|---|---|---|
| Exent rank | — | |
| Price‑target hit rate | 52.4% | |
| Calls up after 12 months | 64.0% | |
| Median 12‑month return of calls | +13.4% | |
| Median days to hit target | 91 days | |
| Stocks covered | 18 | — |
| Time to reach the target | Rudy Li |
|---|---|
| Under 30 days | 6.5% |
| 30–90 days | 32.3% |
| 90–180 days | 22.6% |
| Over 180 days | 38.7% |
Share of the targets that were reached, by how long they took. Targets are usually set for 12 months.
STOK · PRTA · DFTX · PRAX · CNTA · XENE · IMUX · ANRO
In the past year Rudy’s ratings were 88% Buy, 12% Hold and 0% Sell.
| Date | Stock | Action | Rating | Price target |
|---|---|---|---|---|
| Aug 26, 2026 | HRMY | Initiated Coverage: Buy | Buy | $60.00 |
| Aug 11, 2026 | IMUX | Reiterated: Buy | Buy | $25.00 |
| Aug 3, 2026 | STOK | Reiterated: Buy | Buy | $40.00 |
| Jul 29, 2026 | QURE | Upgraded: Buy | Buy | $65.00 |
| Jul 7, 2026 | SPTX | Initiated Coverage: Hold | Hold | $0.00 |
| Jul 7, 2026 | LBRX | Initiated Coverage: Buy | Buy | $45.00 |
| Jul 7, 2026 | CMPS | Reiterated: Buy | Buy | $18.00 |
| May 6, 2026 | ACAD | Reiterated | Buy | $33.00 |
| May 6, 2026 | ACAD | Reiterated: Buy | Buy | $33.00 |
| Apr 6, 2026 | NBIX | Reiterated: Buy | Buy | $160.00 |
| Apr 6, 2026 | NBIX | Reiterated | Buy | $160.00 |
| Apr 6, 2026 | PRAX | Maintained: Buy | Buy | $500.00 |
Ratings from the last 30 days are members‑only in Exent Gems, with the stocks where several top‑ranked analysts agree; older ratings are shown in full.
Exent replays every rating with a price target over a 7‑year lookback: was the target reached, how long it took, and what the stock returned 1, 3, 6 and 12 months after the call. The star rating and rank combine success rate, average return and the number of ratings, so a few lucky calls do not make a top analyst. Statistics as of Jun 24, 2026; ranking updated Oct 20, 2026. How accurate are analyst price targets overall?
Past performance does not guarantee future results. Historical figures are calculated by Exent from market data and are for education only; they are not investment advice or a recommendation to buy or sell any security.
By Exent’s scoring, Rudy Li ranks among the top 50 healthcare analysts in Exent’s ranking, based on a 7-year backtest of price-target hit rate, returns after calls and number of ratings. The exact rank, hit rate and live calls are members-only in Exent Gems (exent.ai/radar). Past accuracy does not guarantee future accuracy.
Rudy Li’s price-target hit rate is part of the members-only record in Exent Gems (exent.ai/radar). For comparison, the average analyst’s price targets were reached 52.4% of the time.
Rudy Li (Wolfe Research) covers 18 stocks, mostly in healthcare. The most frequently rated are STOK, PRTA, DFTX, PRAX, CNTA.
Exent tracks 4,000+ analysts, keeps only the elite few with proven records, and surfaces the Gems where they agree.
Educational content, not investment advice. Examples are illustrative; past performance does not guarantee future results.